To understand the clinical relevance of Rictor/mTORC2 in malignant breast cancers, we assessed RICTOR gene alterations in publicly available datasets curated by TCGA (Cell, N = 817; ref. 26), METABRIC (N = 1904; ref. 27), and TCGA Firehose Legacy (N = 960; refs. 29, 33), finding RICTOR gene amplification or overexpression in 36.6% (N = 299), 14.5% (N = 277), and 33.6% (N = 323) of tumor samples, respectively (Fig. 1A). Here, RICTOR is linked to neoplasm.